

## AMENDMENTS

### Listing of Claims:

The following listing of claims replaces all previous listings or versions thereof:

1 – 19. (Canceled)

20. (Currently Amended) A method of inhibiting angiogenesis in a human individual comprising the step of administering a Corticotropin Releasing Factor Receptor 2 (CRFR2) agonist to said individual; ~~wherein if the individual has cancer, then the method further comprises determining whether angiogenesis has been inhibited in said individual~~ wherein said individual has cancer, and wherein said cancer is not a brain cancer.

21. (Previously presented) The method of claim 20 wherein said CRFR2 agonist is selected from the group consisting of urocortin and corticotropin releasing factor.

22. (Currently amended) The method of claim 20, wherein said CRFR2 agonist inhibits angiogenesis in a tissue selected from the group consisting of heart, ~~brain~~, pituitary, gonad, kidney, adipose, and gastrointestinal tract tissues.

23 – 29. (Canceled)

30. (Currently amended) The method of claim ~~[[24]]~~20, wherein the method further comprises determining whether angiogenesis has been inhibited in said individual.

31. (New) The method of claim 20, wherein said cancer is present in a tissue selected from the group consisting of heart, pituitary, gonad, kidney, adipose, and gastrointestinal tract tissues.